These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
163 related items for PubMed ID: 1665493
1. Effect of rhGM-CSF on haematopoietic reconstitution after chemotherapy in small-cell lung cancer. Havemann K, Klausmann M, Wolf M, Fischer JR, Drings P, Oster W. J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S203-7. PubMed ID: 1665493 [Abstract] [Full Text] [Related]
3. Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study. Pujol JL, Douillard JY, Rivière A, Quoix E, Lagrange JL, Berthaud P, Bardonnet-Comte M, Polin V, Gautier V, Milleron B, Chomy F, Chomy P, Spaeth D, Le Chevalier T. J Clin Oncol; 1997 May; 15(5):2082-9. PubMed ID: 9164221 [Abstract] [Full Text] [Related]
5. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients. Steward WP, von Pawel J, Gatzemeier U, Woll P, Thatcher N, Koschel G, Clancy L, Verweij J, de Wit R, Pfeifer W, Fennelly J, von Eiff M, Frisch J. J Clin Oncol; 1998 Feb; 16(2):642-50. PubMed ID: 9469353 [Abstract] [Full Text] [Related]
8. Sequential studies on the role of mitoxantrone, high-dose cytarabine, and recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of refractory non-Hodgkin's lymphoma. Ho AD, Del Valle F, Haas R, Engelhard M, Hiddemann W, Rückle H, Schlimok G, Thiel E, Andreesen R, Fiedler W. Semin Oncol; 1990 Dec; 17(6 Suppl 10):14-8; discussion 18-9. PubMed ID: 2259918 [Abstract] [Full Text] [Related]
9. Phase I trial of etoposide, doxorubicin and cisplatin (EAP) in combination with GM-CSF. Ford PA, Arbuck SG, Minniti C, Miller LL, DeMaria D, O'Dwyer PJ. Eur J Cancer; 1996 Apr; 32A(4):631-5. PubMed ID: 8695266 [Abstract] [Full Text] [Related]
12. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Bettelheim P, Valent P, Andreeff M, Tafuri A, Haimi J, Gorischek C, Muhm M, Sillaber C, Haas O, Vieder L. Blood; 1991 Feb 15; 77(4):700-11. PubMed ID: 1993213 [Abstract] [Full Text] [Related]
13. Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level. Vadhan-Raj S, Broxmeyer HE, Hittelman WN, Papadopoulos NE, Chawla SP, Fenoglio C, Cooper S, Buescher ES, Frenck RW, Holian A. J Clin Oncol; 1992 Aug 15; 10(8):1266-77. PubMed ID: 1634916 [Abstract] [Full Text] [Related]
15. Comparison of 5 vs 10 micrograms/kg per day of GM-CSF following dose-intensified chemotherapy with cisplatin, etoposide, and ifosfamide in patients with advanced testicular cancer. Bokemeyer C, Schmoll HJ, Metzner B, Beyer J, Illiger HJ, Kneba M, Ostermann H, Kynast B, Räth U, Poliwoda H. Ann Hematol; 1993 Aug 15; 67(2):75-9. PubMed ID: 8347733 [Abstract] [Full Text] [Related]